Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiesi to sell Kamada’s inhaled anti-trypsin therapy over the next 12 years

Executive Summary

Over the next 12 years, Chiesi Farmaceutici SPA (respiratory and critical care diseases) will have exclusive rights to market in Europe, Turkey, and the Commonwealth of Independent States Israeli biotech Kamada Ltd.’s inhaled formulation of alpha-1 antitrypsin (AAT)--in Phase II/III for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can lead to lung or hepatic disorders.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register